Lai H Henry, Boone Timothy B, Appell Rodney A
Rev Urol. 2002;4 Suppl 4(Suppl 4):S28-37.
Immediate-release oxybutynin was the gold standard for pharmacologic treatment of overactive bladder for nearly 30 years. Intolerable systemic side effects, in particular dry mouth, limited its clinical utility, resulting in poor patient compliance with dosing regimens. Multiple studies have demonstrated the vastly superior tolerability of tolterodine, extended-release tolterodine, and extended-release oxybutynin over that of immediate-release oxybutynin at equivalent doses, and in the case of extended-release oxybutynin even to twice the dose of the original immediate-release form. With different drug delivery systems and, perhaps, with better bladder selectivity, these new oral agents have favorable side effect profiles, which translate into higher patient compliance and fewer treatment withdrawals or dosage reductions.
近30年来，速释奥昔布宁一直是治疗膀胱过度活动症的药物治疗金标准。难以耐受的全身性副作用，尤其是口干，限制了其临床应用，导致患者对给药方案的依从性较差。多项研究表明，在等效剂量下，托特罗定、缓释托特罗定和缓释奥昔布宁的耐受性远优于速释奥昔布宁，就缓释奥昔布宁而言，甚至是原速释剂型剂量的两倍。这些新型口服制剂具有不同的给药系统，或许还具有更好的膀胱选择性，副作用较小，这转化为更高的患者依从性以及更少的治疗中断或剂量减少。
